Integra LifeSciences Corp. recalled 5,116 units of the Codman CereLink ICP Sensor Basic Kit on December 12, 2025. The recall stems from potential corrosion stains on the included 14-gauge Tuohy needle. Healthcare providers and patients must stop using the device immediately and follow the recall instructions.
Potential corrosion stains on the surface of the 14-gauge Tuohy Needle that is included in the Microsensor and Cerelink ICP Kits.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Integra LifeSciences Corp. (NeuroSciences) or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The Codman CereLink ICP Sensor Basic Kit, catalog number 826850, includes a nylon tube with a pressure transducer and a 14-gauge Tuohy needle. The kit is used for intracranial pressure monitoring and is compatible with the Codman Cranial Hand Drill. It is distributed worldwide, including the U.S. and several countries.
The recall addresses potential corrosion stains on the surface of the Tuohy needle, which may compromise safety during medical procedures. Corrosion could lead to device malfunction or ineffective pressure monitoring.
No injuries or deaths have been reported related to this issue. The recall is classified as Class II, indicating a potential risk of serious injury.
Patients and healthcare providers should stop using the ICP Sensor Basic Kit immediately. Contact Integra LifeSciences Corp. or your healthcare provider for specific instructions on the recall.
For further assistance, contact Integra LifeSciences Corp. at their official website or customer service number.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.